Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | IKS014 |
| Synonyms | |
| Therapy Description |
IKS014 is an antibody-drug conjugate (ADC) comprising a monoclonal Erbb2 (Her2) antibody linked to the antimicrotubule agent monomethyl auristatin F (MMAF), which has potential antitumor activity against ERBB2 (HER2)-expressing tumor cells (Cancer Res 2022;82(12_Suppl):Abstract nr 1753). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| IKS014 | IKS-014|IKS 014|FS1502|FS-1502|FS 1502 | HER2 (ERBB2) Antibody 79 | IKS014 is an antibody-drug conjugate (ADC) comprising a monoclonal Erbb2 (Her2) antibody linked to the antimicrotubule agent monomethyl auristatin F (MMAF), which has potential antitumor activity against ERBB2 (HER2)-expressing tumor cells (Cancer Res 2022;82(12_Suppl):Abstract nr 1753). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05872295 | Phase I | IKS014 | IKS014 in Advanced Solid Tumors That Express HER2 | Recruiting | USA | NZL | AUS | 1 |